Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

The acquisition of Ambry Genetics will fall under this segment. Ambry generates vast amounts of data across the ~400k patients it sequences each year. Tempus can leverage this data to augment its ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher.All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth ...

Tempus AI reports mixed fourth-quarter financial results. JPMorgan analyst Rachel Vatnsdal downgrades Tempus AI from Overweight to Neutral following the company's quarterly results. Our government ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...